Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Net Income (2016 - 2025)

Historic Net Income for Iradimed (IRMD) over the last 13 years, with Q3 2025 value amounting to $5.6 million.

  • Iradimed's Net Income rose 1043.99% to $5.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.5 million, marking a year-over-year increase of 1907.69%. This contributed to the annual value of $18.5 million for FY2024, which is 1753.58% up from last year.
  • As of Q3 2025, Iradimed's Net Income stood at $5.6 million, which was up 1043.99% from $5.8 million recorded in Q2 2025.
  • In the past 5 years, Iradimed's Net Income registered a high of $5.8 million during Q2 2025, and its lowest value of $1.4 million during Q1 2021.
  • In the last 5 years, Iradimed's Net Income had a median value of $3.9 million in 2021 and averaged $3.8 million.
  • The largest annual percentage gain for Iradimed's Net Income in the last 5 years was 27919.82% (2021), contrasted with its biggest fall of 2161.2% (2021).
  • Iradimed's Net Income (Quarter) stood at $3.9 million in 2021, then fell by 5.63% to $3.7 million in 2022, then fell by 15.13% to $3.1 million in 2023, then soared by 42.7% to $4.4 million in 2024, then rose by 25.34% to $5.6 million in 2025.
  • Its last three reported values are $5.6 million in Q3 2025, $5.8 million for Q2 2025, and $4.7 million during Q1 2025.